Sjogren's Syndrome Market in 7MM is expected to witness a major change in the study period 2019-2032

The increase in prevalent population of Sjogren's Syndrome is a consequence of overall increase in the geriatric population, general increasing prevalence of autoimmune disease, increasing in the presence of its risk factors like autoimmune diseases, etc.

The Sjogren's Syndrome market report provides current treatment practices, emerging drugs, Sjogren's Syndrome market share of the individual therapies, current and forecasted Sjogren's Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Sjogren's Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Sjogren's Syndrome market.

Key takeaways from the Sjogren's Syndrome Market Research Report

• The Prevalence of Sjögren's Syndrome is anticipated to increase during the study period [2019-2032]

• As per the DelveInsight estimates, in 2022, the total gender-specific cases of Sjögren's Syndrome were approximately 175,200 and 1,577,600 cases of males and females, respectively in the United states, which are expected to grow during the study period, i.e., 2019-2032.

• The leading Sjogren's Syndrome Market Companies includes ADVANZ Pharma, Daiichi Sankyo, Novartis/MorphoSys, Resolve Therapeutics, GlaxoSmithKline, VIELABIO, RemeGen, Bristol Myers Squibb, Novartis, TearSolutions, and others.

• Promising Sjogren's Syndrome Pipeline Therapies includes Lanraplenib, Filgotinib, Tirabrutinib, AMG 557/MEDI5872, Parsaclisib, VIB4920, VAY736, PRFs, RSLV-132, CFZ533, and others.

Discover which therapies are expected to grab the major Sjogren's Syndrome Market share, click here for Sjogren's Syndrome Market Research Report @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sjogren's Syndrome Overview

Sjogren's Syndrome (SS) is an autoimmune disorder caused by the lymphocytic infiltration of exocrine glands resulting in glandular dysfunction, preferentially of the salivary and lacrimal glands. It can be classified into two types, i.e., Primary Sjogren's Syndrome, and Secondary Sjogren's Syndrome. Primary Sjogren's Syndrome (pSS) occurs in the absence of other autoimmune diseases and is characterized by keratoconjunctiva sicca (dry eyes) and xerostomia (dry mouth), collectively called the sicca syndrome. In contrast, Secondary Sjogren's Syndrome presents, along with other autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Sjogren's Syndrome Epidemiology Segmentation in the 7MM

• Total Sjogren's Syndrome Diagnosed Prevalent Cases
• Total Sjogren's Syndrome Severity-Specific Cases
• Total Sjogren's Syndrome Antibody-Specific Cases
• Total Sjogren's Syndrome Type-Specific Cases

Download the report to understand which factors are driving Sjogren's Syndrome Market Trends, click here for Sjogren's Syndrome Market Forecast @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sjogren's Syndrome Treatment Market
Currently, the Sjogren's Syndrome therapeutic market size is mainly accounted by symptomatic treatment using the local therapies like pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and, systemic therapies like corticosteroids, hydroxychloroquine, immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid). Local therapy generally comprises the treatment of sicca symptoms. For the dry-eyes treatment, tear substitution therapy including high-viscosity eye drops and gels, combined with oral mucolytic agents to dissolve mucus, is the mainstay in Sjogren's Syndrome treatment. Drugs with a systemic effect, secretagogues, such as pilocarpine and cevimeline, were approved by the US FDA to treat dry eyes and mouth in Sjogren's Syndrome patients.

Sjogren's Syndrome Companies and Therapies

• RSLV-132: Resolve Therapeutics
• VAY736: Novartis/MorphoSys
• CFZ533: Novartis
• Belimumab: GlaxoSmithKline
• RO5459072: Roche
• LOU-064: Novartis
• Abatacept: Bristol Myers Squibb
• Lacripep: TearSolutions
• Parsaclisib: Incyte Corporation
• Filgotinib: Galapagos NV /Gilead Sciences
• GS-9876: Gilead Sciences
• VIB7734: VIELABIO

Learn more about the Sjogren's Syndrome FDA-approved drugs, click here for Sjogren's Syndrome Treatment Market @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sjogren's Syndrome Market Report

• Coverage- 7MM

• Sjogren's Syndrome Companies- ADVANZ Pharma, Daiichi Sankyo, Novartis/MorphoSys, Resolve Therapeutics, GlaxoSmithKline, VIELABIO, RemeGen, Bristol Myers Squibb, Novartis, TearSolutions, and others.

• Sjogren's Syndrome Pipeline Therapies- Lanraplenib, Filgotinib, Tirabrutinib, AMG 557/MEDI5872, Parsaclisib, VIB4920, VAY736, PRFs, RSLV-132, CFZ533, and others

• Sjogren's Syndrome Market Dynamics: Sjogren's Syndrome Market Drivers and Barriers

Discover more about Sjogren's Syndrome Drugs in development, click here for Sjogren's Syndrome Market Drugs @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Sjogren's Syndrome
3. Competitive Intelligence Analysis for Sjogren's Syndrome
4. Sjogren's Syndrome: Market Overview at a Glance
5. Sjogren's Syndrome: Disease Background and Overview
6. Patient Journey
7. Sjogren's Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Sjogren's Syndrome Unmet Needs
10. Key Endpoints of Sjogren's Syndrome Treatment
11. Sjogren's Syndrome Marketed Products
12. Sjogren's Syndrome Emerging Therapies
13. Sjogren's Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Sjogren's Syndrome Market Outlook
16. Access and Reimbursement Overview of Sjogren's Syndrome
17. KOL Views
18. Sjogren's Syndrome Market Drivers
19. Sjogren's Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

To read more about the Sjogren's Syndrome Market Dynamics of the report, click here for Sjogren's Syndrome Market Barriers and Drivers @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.